DXM + Ritonavir, alone or in ritonavir-boosted regimens

https://dxm-atlas.org/en/interactions/ritonavir/

Compare

Key points for this combination

Human tests that use substances to measure metabolic activity give different results across treatment regimens and measurements. They do not show a uniformly strong effect on the CYP2D6 enzyme [45, 46].

General concepts in this text

Enzyme

A protein that helps chemical transformations in cells.

A transformation can build or break down a substance.

Sources: Enzyme

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

Drug metabolism

Chemical transformation of a medicine in the body.

The resulting substances are metabolites. Transformation can reduce or increase pharmacological activity.

Sources: Drug metabolism

How well is this understood?

Mechanism confidence: high

Confidence in the mechanism: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Confidence in human DXM data: medium

Confidence in direct human evidence involving DXM: medium

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Measurements of drug concentration or metabolism.

How to read ratings and study limits

How do the substances interact?

Can the amount reaching the body change?

Mechanism: 2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
3A — CYP3A metabolism
ⓘ

CYP3A

A group of related CYP enzymes involved in the chemical transformation of medicines.

CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.

Sources: CYP3A
  1. In a study of 13 healthy CYP2D6 extensive metabolizers, a low ritonavir booster regimen did not significantly change the urinary DXM/DXO metabolic ratio or convert participants to poor-metabolizer status. Finding below: Finding [45] · 3
  2. A different probe, desipramine, nevertheless detected modest CYP2D6 inhibition [45]. Finding below: Finding [45] · 1
  3. Plasma DXM-to-DXO AUC ratio increase → In a separate study of HIV-infected patients receiving ritonavir-boosted lopinavir, the plasma DXM-to-DXO AUC ratio increased 2.92-fold in extensive metabolizers [46]. Finding below: Finding [46]

What remains unknown?

The magnitude of the interaction depends on the regimen, population and measure studied. Direct pharmacokinetic results are presented with each study’s conditions; this heterogeneous group has its own row.

The 2.92-fold change concerns the ratio of two AUCs — DXM and DXO.

Sources

Check the review’s wording

*Direct human metabolic-probe data differ between regimens and endpoints; not a uniform strong CYP2D6 effect [45, 46]

Combination row in the review: 3A — CYP3A metabolism / 2D6 — CYP2D6 metabolism

Evidence and sources

Research publication

[45] · Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers · 2005

Finding [45] · 3

What was found?

In a study of 13 healthy CYP2D6 extensive metabolizers, a low ritonavir booster regimen did not significantly change the urinary DXM/DXO metabolic ratio or convert participants to poor-metabolizer status.

Finding [45] · 2

Finding [45] · 1

What was found?

A different probe, desipramine, nevertheless detected modest CYP2D6 inhibition [45].

What limits this finding?

The magnitude of the interaction depends on the regimen, population and measure studied. Direct pharmacokinetic results are presented with each study’s conditions; this heterogeneous group has its own row.

Scientific review: Ritonavir and regimen-dependent effects

Research publication

[46] · Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients · 2008

Finding [46]

What was found?

In a separate study of HIV-infected patients receiving ritonavir-boosted lopinavir, the plasma DXM-to-DXO AUC ratio increased 2.92-fold in extensive metabolizers [46].

What limits this finding?

The 2.92-fold change concerns the ratio of two AUCs — DXM and DXO.

Scientific review: Ritonavir and regimen-dependent effects

Related entries

Reference

Open the source and related combinations →